Generex Biotechnology Corp. (GNBT, Financial) filed Quarterly Report for the period ended 2008-10-31.
Generex Biotechnology Corp. is engaged in the research and development of drug delivery technology primarily involving the administration of proprietary formulations of large molecule drugs to the oral cavityusing a hand-held aerosol applicator. Large molecule drugs have been approved for sale in the United States or are presently undergoing clinical trials as part of the process to obtain such approval including various proteins peptides monoclonal antibodies hormones and vaccines. Generex Biotechnology Corp. has a market cap of $72.18 million; its shares were traded at around $0.49 with and P/S ratio of 563.92.
Read the The complete Report
More on GNBT:
Gurus buys and sells of GNBT
10-year financial history of GNBT.
Insider buys/sells of GNBT.
Generex Biotechnology Corp. is engaged in the research and development of drug delivery technology primarily involving the administration of proprietary formulations of large molecule drugs to the oral cavityusing a hand-held aerosol applicator. Large molecule drugs have been approved for sale in the United States or are presently undergoing clinical trials as part of the process to obtain such approval including various proteins peptides monoclonal antibodies hormones and vaccines. Generex Biotechnology Corp. has a market cap of $72.18 million; its shares were traded at around $0.49 with and P/S ratio of 563.92.
Highlight of Business Operations:
Read the The complete Report
More on GNBT:
Gurus buys and sells of GNBT
10-year financial history of GNBT.
Insider buys/sells of GNBT.
